My Account
Follow us on:
Powered By
See the top gainers, losers, invest and get updated what's happening in the crypto market
Invest Now
Discover the secret world of unlisted shares — analyse India's top pre-IPO companies and invest before they hit the markets
Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.
You are already a Moneycontrol Pro user.